Druggability of Proteins/Enzymes
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: closed (15 May 2022) | Viewed by 5959
Special Issue Editors
Interests: prostate cancer; bladder cancer; natural products research; biomarkers; targeted therapy; miRNA; mechanisms of chemoresistance
Special Issues, Collections and Topics in MDPI journals
Interests: cancer research; transcriptomics; metabolomics; proteomics; Pharmacognosy; molecular genetics; cell biology; molecular physiology; drug discovery
Special Issue Information
Dear Colleagues,
This Special Issue will cover all aspects of research works on druggable proteins and enzymes.
The human genome encodes approximately 20,000 proteins, a handful of which are suitable for drug–protein interactions. Within this group, even fewer are effectively targeted by drugs. This subgroup is defined here as the druggable proteins/enzymes with a specific affinity to bind small molecule(s) or antibodies mediating a signal transduction network involved in disease control.
Suitable manuscripts include, but are not limited to, research and review manuscripts that address enzyme and protein activities targeted by drugs converting signal transduction from the site of interaction into specific responses inside the cell resulting, for example, in gene expression, cell division, and/or cell death.
Research works of antibody-based drugs that cannot pass the plasma membrane are also welcome as they are mostly directed against protein targets on the cell surface (receptors) affecting their activities.
Additional druggable proteins that are of interest include, but are not limited to, all works on transporters, G-protein coupled receptors, CD markers, nuclear receptors, voltage-gated ion channels, etc.
Dr. Ruth Vinall
Dr. Simeon Kotchoni
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug
- antibodies
- enzymes
- target
- druggable proteomics
- druggable enzymolomics
- disease
- signal transduction
- transporters
- channel proteins
- cell division
- cell death
- pathway inhibition
- gene expression
- computational biology
- vaccine
